Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

PF584 C‐MYC‐DRIVEN AND PRMT5‐DEPENDENT REGULATION OF MULTIPLE MYELOMA CELL PROLIFERATION THROUGH SMCHD1 GENE

View through CrossRef
Background:The protein arginine methyltransferase 5 (PRMT5) catalyzes the symmetrical bimethylation of arginine residues, which plays an important regulatory role in the life process. Transcription factor c‐Myc is widely proved involved in the alteration and development of tumors, while the regulatory mechanism of c‐Myc‐mediated gene expression has not been fully understood.Aims:In this article we try to investigate the functional role of PRMT5 and c‐Myc in regulating multiple myeloma cell proliferationMethods:The protein and mRNA expression levels of PRMT5 in myeloma cells and normal cells were detected by Western Blot and qPCR. Lentivirally transduced shRNAs targeting PRMT5 (sh‐PRMT5) was constructed using lentivirus mediated RNAi technology, and was packaged to infect MM cells to select positive colonies. The effect of PRMT5 on the proliferation of MM cells was detected by cck‐8 assay. Annexin V/7‐AAD double staining flow cytometry was used to detect cell survival and apoptosis rate. The expression of apoptotic suppressor gene c‐Myc in sh‐PRMT5 cell lines was detected by Western Blot and qPCR. Finally, double‐knockdown of PRMT5 and c‐myc was performed and gene expression differentiation were identified by RNA sequencing (RNA‐seq).Results:PRMT5 expression in MM cell lines (RPMI8226 and U266) was relatively high compared with peripheral blood mononuclear cells (PBMCs), which was correlated with progression‐free survival (PFS) and overall survival (OS) in MM patients. After sh‐PRMT5 infection to MM cell lines, puromycin selection was performed and efficient gene knockdown was evaluated by Western Blot and qPCR. After targeted silencing of PRMT5 expression, the proliferation of MM cells was decreased and apoptosis was significantly increased (P < 0.05). C‐Myc protein and mRNA levels were significantly downregulated after PRMT5 gene silencing. The results showed that PRMT5 promoted the proliferation of MM cells and inhibited the apoptosis of MM cells by regulating the expression of apoptotic suppressor gene c‐Myc. Subsequently, RNA‐seq confirmed SMCHD1 as the common candidate target gene of c‐myc and PRMT5. Therefore, we speculated that PRMT5 and c‐Myc may jointly regulate SMCHD1 gene to promote the proliferation of MM cells.Summary/Conclusion:Altogether, our study not only proposed the mechanism PRMT5 and c‐myc in regulating multiple myeloma related gene expression, but also provided a new strategy and theoretical basis for clinical treatment of multiple myeloma.
Title: PF584 C‐MYC‐DRIVEN AND PRMT5‐DEPENDENT REGULATION OF MULTIPLE MYELOMA CELL PROLIFERATION THROUGH SMCHD1 GENE
Description:
Background:The protein arginine methyltransferase 5 (PRMT5) catalyzes the symmetrical bimethylation of arginine residues, which plays an important regulatory role in the life process.
Transcription factor c‐Myc is widely proved involved in the alteration and development of tumors, while the regulatory mechanism of c‐Myc‐mediated gene expression has not been fully understood.
Aims:In this article we try to investigate the functional role of PRMT5 and c‐Myc in regulating multiple myeloma cell proliferationMethods:The protein and mRNA expression levels of PRMT5 in myeloma cells and normal cells were detected by Western Blot and qPCR.
Lentivirally transduced shRNAs targeting PRMT5 (sh‐PRMT5) was constructed using lentivirus mediated RNAi technology, and was packaged to infect MM cells to select positive colonies.
The effect of PRMT5 on the proliferation of MM cells was detected by cck‐8 assay.
Annexin V/7‐AAD double staining flow cytometry was used to detect cell survival and apoptosis rate.
The expression of apoptotic suppressor gene c‐Myc in sh‐PRMT5 cell lines was detected by Western Blot and qPCR.
Finally, double‐knockdown of PRMT5 and c‐myc was performed and gene expression differentiation were identified by RNA sequencing (RNA‐seq).
Results:PRMT5 expression in MM cell lines (RPMI8226 and U266) was relatively high compared with peripheral blood mononuclear cells (PBMCs), which was correlated with progression‐free survival (PFS) and overall survival (OS) in MM patients.
After sh‐PRMT5 infection to MM cell lines, puromycin selection was performed and efficient gene knockdown was evaluated by Western Blot and qPCR.
After targeted silencing of PRMT5 expression, the proliferation of MM cells was decreased and apoptosis was significantly increased (P < 0.
05).
C‐Myc protein and mRNA levels were significantly downregulated after PRMT5 gene silencing.
The results showed that PRMT5 promoted the proliferation of MM cells and inhibited the apoptosis of MM cells by regulating the expression of apoptotic suppressor gene c‐Myc.
Subsequently, RNA‐seq confirmed SMCHD1 as the common candidate target gene of c‐myc and PRMT5.
Therefore, we speculated that PRMT5 and c‐Myc may jointly regulate SMCHD1 gene to promote the proliferation of MM cells.
Summary/Conclusion:Altogether, our study not only proposed the mechanism PRMT5 and c‐myc in regulating multiple myeloma related gene expression, but also provided a new strategy and theoretical basis for clinical treatment of multiple myeloma.

Related Results

PRMT5 Inhibition Affects RNA Methylation and Is a Potential Therapeutic Target in BPDCN
PRMT5 Inhibition Affects RNA Methylation and Is a Potential Therapeutic Target in BPDCN
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically aggressive hematologic cancer that arises from malignant transformation of plasmacytoid dendritic cell...
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma
Mantle cell lymphoma (MCL) with MYC rearrangement (MYC-R) is rare and little is known about the importance of MYC extra copies (EC) in the absence of MYC-R in MCL patients. This st...
Improving immunotherapy in high-grade B-cell lymphoma
Improving immunotherapy in high-grade B-cell lymphoma
MYC is a transcription factor that upon deregulation acts as an oncogene. Cancer patients with MYC overexpression face significant worse outcomes to treatment with (immuno)chemothe...
Abstract 5833: Targeting the transcription co-activator TAZ inhibits MYC-driven medulloblastoma
Abstract 5833: Targeting the transcription co-activator TAZ inhibits MYC-driven medulloblastoma
Abstract Medulloblastoma (MB), the most common malignant pediatric brain tumor, results in significant neurological, intellectual and physical disability or death. F...
Abstract 1872: Targeting MYC-driven medulloblastoma using inhibitors of glutamine metabolism.
Abstract 1872: Targeting MYC-driven medulloblastoma using inhibitors of glutamine metabolism.
Abstract Medulloblastoma is the most common malignant brain tumor in children. Currently, treatment consists of surgical resection, chemotherapy, and whole brain and...
Abstract 1829: Characterization of factors affecting sensitivity and resistance to PRMT5 inhibition in glioblastoma
Abstract 1829: Characterization of factors affecting sensitivity and resistance to PRMT5 inhibition in glioblastoma
Abstract BACKGROUND: Glioblastoma (GBM) is a highly infiltrative and aggressive malignancy with few treatment options; all patients develop recurrence after initial ...
Abstract 1725: Role of PRMT5 in neuroendocrine prostate cancer development
Abstract 1725: Role of PRMT5 in neuroendocrine prostate cancer development
Abstract Background: Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer responsible for an estimated 20-30% of castration resistant prostat...

Back to Top